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We prospectively studied 298 patients with cystic fibro-
sis (mean age 11.3 years; range 2 months to 32 years; sex
ratio, 0.47) for nontuberculous mycobacteria in respiratory
samples from January 1, 1996, to December 31, 1999.
Mycobacterium abscessus was by far the most prevalent
nontuberculous mycobacterium: 15 patients (6 male, 9
female; mean age 11.9 years; range 2.5–22 years) had at
least one positive sample for this microorganism (versus 6
patients positive for M. avium complex), including 10 with
>3 positive samples (versus 3 patients for M. avium com-
plex). The M. abscessus isolates from 14 patients were
typed by pulsed-field gel electrophoresis: each of the 14
patients harbored a unique strain, ruling out a common
environmental reservoir or person-to-person transmission.
Water samples collected in the cystic fibrosis center were
negative for M. abscessus. This major mycobacterial
pathogen in children and teenagers with cystic fibrosis
does not appear to be acquired nosocomially.
S
ince 1990, an increasing number of studies have
reported the recovery of nontuberculous mycobacteria
from the respiratory tract of patients with cystic fibrosis
(1–4).  Mycobacterium abscessus (formerly  M. chelonae
subsp.  abscessus), a rapidly growing mycobacterium of
the M. fortuitum complex, is of particular concern. It can
cause severe lung disease, which spontaneously advances
until it becomes debilitating or fatal (5,6). It may be
responsible for disseminated infections in patients
undergoing lung transplantation (7). This organism is
usually also susceptible to only a few drugs (8), and some
strains may exhibit multidrug resistance (7).
The frequency of isolation of M. abscessus in cystic
fibrosis patients is unclear. Many studies on
nontuberculous mycobacteria in such patients did not
distinguish M. abscessus and M. chelonae, formerly two
subspecies of M. chelonae, and used the designation M.
chelonae–M. abscessus, M. chelonae group, or even M.
fortuitum complex. Moreover, most studies were
conducted with adults (1,2,4). How cystic fibrosis patients
become contaminated is also poorly understood. M.
abscessus has been reported to be acquired iatrogenically
in non–cystic fibrosis patients (9). The members of the M.
fortuitum complex are saprophytic organisms living in soil
and water that are ubiquitous in hospital environments and
survive well in adverse conditions (10–13). Aerosols,
pulmonary function equipment, and bronchoscopes are
thus potential sources of contamination for patients with
cystic fibrosis. Alternatively, transmission from patients to
patients attending the same department-care facilities
might occur, although this finding has been recently
challenged (14).
We encountered one case of M. abscessus infection in a
patient with cystic fibrosis in 1995. The recovery of this
unusual pathogen prompted us to prospectively evaluate
the rate of isolation of M. abscessus in the cystic fibrosis
patients attending our center, the degree of transmissibility
of this organism, and its clonality, by using DNA-based
identification and typing systems. 
Patients and Methods
Description of Study
All patients with cystic fibrosis who attended the
pediatric department of Necker Hospital for Sick Children
from January 1, 1996, to December 31, 1999, provided at
least one sputum sample per year, which was processed for
the culture of acid-fast bacilli (AFB). Patients who
provided a positive sample then submitted >3 sputum
samples for AFB smear and culture over the next 3
months. AFB smears and cultures were checked quarterly
thereafter.
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Specimens were decontaminated with NALC-NaOH-
oxalic acid (0.25% N-acetyl-L-cysteine–1% sodium
hydroxide–5% oxalic acid) (15). AFB smears were stained
with auramine-rhodamine and scored as previously
described (16). Two Löwenstein-Jensen slants were
inoculated for each specimen, one of which was incubated
at 37°C and the other at 30°C. The slants were examined
twice weekly for 2 weeks and then weekly for a further 10
weeks.
Environmental Samples
Water samples taken from the hospital’s hot and cold
water supply systems were collected in sterile plastic
bottles. Samples (100 mL) were decontaminated with 1%
NaOH without prior concentration by filtration (17). The
inner surfaces of respiratory devices (e.g., nebulizers,
bronchoscopes) were rinsed with 1 to 10 mL of sterile
distilled water; the water used for rinsing was processed
for the culture of AFB without prior decontamination with
1% NaOH.
Species Identification
Rapidly growing mycobacteria recovered from clinical
and environmental samples were identified by standard
techniques (17) and hsp65 sequencing (18). The M. avium
complex was identified by the AccuProbe technique (Gen-
Probe Inc., San Diego, CA). The hsp65 genomovars of M.
abscessus were referred to as T (identical to the type-strain
M. abscessus ATCC 19977T), -5a (differing from ATCC
19977T by 5 nt, and identical to the reference strain M.
abscessus IP970272), -5b (differing from ATCC 19977T by
5 nt, and identical to the reference strain M. abscessus
IP970453), and –6 (differing from ATCC 19977T by 6 nt,
and identical to the reference strain M. abscessus
IP140420009), as previously described (18).
PFGE Analysis
M. abscessus isolates were analyzed by PFGE as
described by Wallace et al., with minor modifications (9).
Restriction fragments obtained after digestion with DraI
and XbaI were separated in 0.5 x TBE buffer (0.025 M
Tris, 0.5 mM EDTA, and 0.025 M boric acid)
supplemented with 50 µM thiourea (19), using a CHEF-
DR III system (Bio-Rad, Richmond, CA) at 14°C and 6
V/cm2. Pulse times were ramped linearly from 1.5 to 21.5
s for 23 h. A size standard (bacteriophage ? concatemers)
was run in parallel in each experiment. Restriction patterns
were analyzed with the Taxotron package (Taxolab
Software, Institut Pasteur, Paris, France) comprising the
RestrictoScan, RestrictoTyper, Adanson, and Dendrograph
programs. 
Results
Screening the Study Population for 
Nontuberculous Mycobacteria 
A total of 298 patients with cystic fibrosis (1,525
sputum samples; mean of 5.0 samples per patient)
followed up at our institution were screened for M.
abscessus from January l, 1996, to December 31, 1999.
The age of the patients ranged from 2 months to 32 years
(mean 11.3 years). The sex ratio was 0.47 (140 male/158
female patients). Samples from two patients could not be
analyzed because the samples were repeatedly
contaminated (<1 interpretable culture per year during the
study period). Of the 296 patients with interpretable
cultures, 29 (9.80%) provided at least one sample positive
for nontuberculous mycobacteria. Twelve of the 296
patients had M. abscessus alone, 3 had M. abscessus and
M. gordonae, 6 had M. avium complex, 4 had M.
gordonae, 1 had M. fortuitum, 1 had M. kansasii, and 2 had
organisms not related to any known species. Thirteen
patients provided at least three positive samples, 10
involving M. abscessus and 3 M. avium complex. Two of
these patients were twin sisters, one colonized with M.
abscessus (patient no. 5) and the other with M. avium
complex.
Description of Cases with M. abscessus Isolation
Fifteen (5%) of the 296 patients with interpretable
cultures provided at least one sample positive for M.
abscessus. Ten of these patients had >3 positive samples,
including six with positive AFB smears (Table).
Mycobacterial disease was documented in four patients: a
16-year-old boy (patient no. 4) with parenchymal
condensation of the left lower lobe on chest x-ray and
computed tomographic (CT) scan, which disappeared only
under anti–M. abscessus treatment; a 10-year-old boy
(patient no. 6), whose rapidly deteriorating and ultimately
fatal condiction was associated with diffuse bronchiectasis
on CT scan; a 9-year-old girl (patient no. 7), who had a
massive, granulomatous pneumonia of the right lung that
led to pneumonectomy, and who died after 15 months of
bacteriologically ineffective anti–M. abscessus treatment;
and a 2-1/2-year-old girl (patient no. 8) with segmental
condensation of the right mid-lobe on chest x-ray and CT
scan, which disappeared only under anti–M. abscessus
treatment. 
All but one (patient no. 1) of the 15 patients were
recognized during the study period. Some of the patients
who were identified in the first year may have previously
gone undetected, as nontuberculous mycobacteria had not
been sought before (patients nos. 2, 3, 4, 5, and 7). The M.
abscessus isolates belonged to genomovars T, -5a, and -6,
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Genomovar T was involved in the two fatal cases recorded
during the study period (patients nos. 6 and 7).
Characteristics of Patients Positive for M. abscessus
The 15 patients positive for M. abscessus were
predominantly females (sex ratio, 0.40). Their mean age at
the time of the first culture positive for M. abscessus (11.9
years, range 2.5–22 years) was very similar to the mean
age of the entire study population. However, the mean age
was lower than that for patients positive for M. avium
complex (17.5 years; range 13–25 years). Of the 14
patients who underwent genotype analysis, 8 were
homozygous for deletion of the phenylalanine in position
508, and 4 were heterozygotous for this deletion plus
another mutation. Pulmonary function at the time of the
first isolation of M. abscessus was highly variable, with
forced expiratory volume in 1 second and forced vital
capacity values ranging from 14% to 99%, and 31% to
104% of predicted values, respectively. Schwachman
score (20) also greatly varied among patients (range
40–85). The most prevalent associated disorders included
bronchiectasis (13 cases), gastroesophageal reflux (3
cases), and allergic bronchopulmonary aspergillosis (3
cases). All patients had pancreatic insufficiency. Nine of
the 15 patients were colonized (at least three positive
sputum samples within the previous 12 months) with
Pseudomonas aeruginosa. None was colonized with
Burkholderia cepacia. 
We analyzed records of all treatments received by the
patients within the 12 months preceding the first isolation
of M. abscessus, including therapeutic aerosols. All of the
patients had received IV antibiotics (1–5 two-week IV
courses; median 3 courses), combined with aerosol
antibiotics at home in 11 patients (tobramycin, 3 patients;
colistin, 8 patients). Six patients had received aerosolized
deoxyribonuclease. Two patients had received oral
corticosteroids, and four had received inhaled
corticosteroids.
Environmental Study
A total of 93 water samples collected from 40 water
supply points in the cystic fibrosis center were studied.
Three samples (3.2%) from two water supply points tested
positive for rapidly growing mycobacteria (M.
mucogenicum, two samples; M. peregrinum: one sample).
None of the samples tested positive for M. abscessus.
None of the 12 respiratory devices (3 bronchoscopes, 9
nebulizers) studied in October 1997 tested positive for any
nontuberculous mycobacteria.
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Table. Chronology of case-patients with Mycobacterium abscessus isolation  
Case no.  Age (y)/sex 
Date of first 
isolation 
No. of pos. 
cultures/total AFB
a 
cultures
b 
No. of pos. AFB 
smears/total AFB smears
b,c  hsp65 genomovar
d 
Sputum 
microbiologic results
e 
1  2.5 / M  Jan 1996  37/48  19/31  (+++)  -6  Negative 
2  13 / F  Feb 1996  2/14  0/9    T  Pseudomonas aeruginosa 
3  15 / F  Apr 1996  3/41  0/21    -5a  P. aeruginosa 
4  16 / M  Apr 1996  5/8  1/6  (+)  T  P. aeruginosa, 
Staphylococcus aureus, 
Aspergillus fumigatus 
5  14 / F  May 1996  8/11  4/8  (++)  T  P. aeruginosa, S. aureus,  
A. fumigatus 
6  10 / M  May 1996  4/25  0/12    T  P. aeruginosa,  
Alcaligenes xylosoxidans 
7  9 / F  May 1996  8/8  4/7  (+++)  T  P. aeruginosa,  
Aspergillus fumigatus 
8  2.5 / F  Nov 1997  4/6  2/5  (++)  -5a  Negative 
9  7 / F  July 1998  2/24  0/7    -5a  S. aureus 
10  17 / M  Sept 1998  3/9  0/6    T  S. aureus, Haemophilus 
influenzae, 
Stenotrophomonas 
maltophilia, A. fumigatus 
11  8 / F  Sept 1998  3/12  0/4    T  P. aeruginosa, 
Staphylococcus aureus 
12  18/F  July 1999  1/5  0/3    T  P. aeruginosa, A. fumigatus 
13  9/M  Sept 1999  1/6  0/3    -6  S. aureus 
14  16/M  Oct 1999  5/13  4/6  (+)  -5a  S. aureus, A. fumigatus 
15  22/F  Nov 1999  1/6  0/3    -6  P. aeruginosa, S. aureus 
aAFB, acid-fast bacilli.
 
bSamples obtained from patients from January 1996 to December 2000; only samples obtained before the administration of antimycobacterial drugs are considered in 
treated patients. 
cSymbols in parentheses: AFB density. 
dSee Methods.  
eOrganisms recovered from at least three sputum samples within the 12 months before the first isolation of M. abscessus. PFGE Analysis of M. abscessus Isolates
PFGE was used to compare the isolates from 14
patients positive  for M. abscessus (the isolates from
patient no. 7 could not be subcultured for testing because
of inadequate storage). We studied all isolates from each
patient who provided <3 positive cultures and a maximum
of five isolates from each patient with >3 isolates. The
isolates from three patients (patients nos. 6, 11, and 12)
gave unreadable restriction patterns with classical
protocols, despite multiple attempts. This phenomenon is
common with mycobacteria, particularly M. abscessus (9)
and is probably related to Tris-dependent site-specific
cleavage of the DNA (19). Nondegradative PFGE was
only achieved by running gels in the presence of thiourea,
which has been shown to protect the DNA from strand
cleavage (21). We were therefore able to type all isolates
from the 14 patients by PFGE. Each of these 14 patients
had isolates of a unique genotype that was unrelated to the
genotype of any other patient (Figure). No differences
were detected between isolates from the same patient (data
not shown), even if the interval between the first and last
isolation was as long as 4 years (patient no. 1).
Discussion
M. abscessus was the predominant nontuberculous
mycobacterium recovered from the patients attending our
center. Approximately 5% of the patients we screened
provided at least one sputum sample positive for this
organism, and >65% of these patients had >3 positive
samples. Other rapidly growing mycobacteria were far
behind (M. fortuitum, one patient). This finding confirms
that M. abscessus differs from M. chelonae and from other
members of the M. fortuitum complex by its particular
propensity to cause lung disease in a variety of clinical
settings. In a series of 154 cases of lung infection caused
by rapidly growing mycobacterium in patients with and
without cystic fibrosis, >80% of isolates were M.
abscessus;  M. fortuitum was isolated in <15% and M.
chelonae in <1% of patients (22). 
In contrast with other studies on cystic fibrosis
populations composed of teenagers and adults (2,4), we
found that the M. avium complex was isolated less
frequently, with an overall prevalence (percentage of
patients with at least one positive nontuberculous
mycobacterial culture) of approximately 2%. Other
pediatric cystic fibrosis centers have reported similar
findings (23,24). This finding suggests that M. abscessus is
the most prevalent mycobacterial pathogen in children and
teenagers with cystic fibrosis. This finding is further
supported by the lack of cases involving M. avium
complex in patients <13 years of age. However, this
finding does not preclude epidemiologic variations
between countries or institutions.
Nosocomial acquisition of M. abscessus has been well
documented in patients without cystic fibrosis. Several
nosocomial outbreaks of infection or pseudoinfection have
been attributed to this organism after cardiac surgery,
bacteremia associated with hemodialysis, and
pseudoinfections due to contaminated bronchoscopes (9).
Epidemiologic investigations showed that these outbreaks
resulted from the use of contaminated water. Disinfectants
may be ineffective against M. abscessus in real conditions
of use (12). PFGE has been used to retrospectively analyze
the clinical and environmental isolates recovered during
M. abscessus outbreaks (9). Each of the outbreaks with
typeable isolates clearly involved a single strain, which
was usually recovered from the water supply system. 
Our results do not support nosocomial acquisition of M.
abscessus. First, the recovery rate of this organism
remained constantly low throughout the study. Previous
nosocomial outbreaks involving patients without cystic
fibrosis were characterized by much higher attack rates.
Second, we did not find any link between the use of
respiratory devices and the acquisition of M. abscessus.
Patients positive for M. abscessus did not receive more
aerosol treatments than did patients with similar clinical
status (not shown). The patients used their personal
nebulizer at the center and received aerosols in their own
rooms. Sterile saline was used when the aerosol was
mixed. Reusable respiratory devices were disinfected
according to validated protocols and were washed
exclusively with sterile water. During the study period, no
patients without cystic fibrosis, even severely
immunocompromised ones, were infected with M.
abscessus as a result of a contaminated bronchoscope in
our pediatric department. Third, although various rapidly
growing mycobacteria were recovered from several water
supply points in our center, M. abscessus was not isolated.
Finally, PFGE analysis demonstrated that the cases
involved unrelated strains, which argues against a common
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Figure. Pulsed-field gel electrophoresis analysis of DraI-digested
DNA from Mycobacterium abscessus isolates. Restriction patterns
of isolates from 14 patients are shown, with a dendrogram of sim-
ilarity; λ concatemers were used as size standards. source of contamination or patient-to-patient transmission.
Similar results have been recently reported with fewer
patients (14). The low transmissibility, if any, of M.
abscessus from person to person is further supported by
the observation of twin sisters in our series, only one of
whom was colonized with M. abscessus.
Whether specific measures are necessary to prevent M.
abscessus infection in patients with cystic fibrosis is
questionable (14). Our epidemiologic results indicate that
few potential control approaches exist. Astrict segregation
policy seems unnecessary because apparently no risk of
person-to-person transmission of M. abscessus exists (14,
this study). Further epidemiologic studies are required
before recommendations for infection-control precautions
can be formulated. 
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